| 20.1 BPD symptom severity ‐ antipsychotics vs placebo by class (1st vs 2nd generation) |
7 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 20.1.1 1st generation |
2 |
108 |
Std. Mean Difference (IV, Random, 95% CI) |
0.29 [‐0.09, 0.67] |
| 20.1.2 2nd generation |
5 |
820 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.36 [‐0.66, ‐0.05] |
| 20.2 Suicide‐related outcomes ‐ antipsychotics vs placebo by class (1st vs 2nd generation) |
7 |
854 |
Std. Mean Difference (IV, Random, 95% CI) |
0.05 [‐0.18, 0.29] |
| 20.2.1 1st generation |
2 |
103 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.20 [‐1.26, 0.86] |
| 20.2.2 2nd generation |
5 |
751 |
Std. Mean Difference (IV, Random, 95% CI) |
0.07 [‐0.17, 0.31] |
| 20.3 Psychosocial functioning ‐ antipsychotics vs placebo by class (1st vs 2nd generation) |
7 |
904 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.16 [‐0.33, ‐0.00] |
| 20.3.1 1st generation |
3 |
164 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.12 [‐0.67, 0.42] |
| 20.3.2 2nd generation |
4 |
740 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.17 [‐0.32, ‐0.03] |
| 20.4 BPD symptom severity ‐ antipsychotics vs placebo by substance |
7 |
928 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.21 [‐0.49, 0.08] |
| 20.4.1 Haloperidol |
1 |
58 |
Std. Mean Difference (IV, Random, 95% CI) |
0.30 [‐0.22, 0.82] |
| 20.4.2 Olanzapine |
2 |
596 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.15 [‐0.41, 0.10] |
| 20.4.3 Thiothixene |
1 |
50 |
Std. Mean Difference (IV, Random, 95% CI) |
0.28 [‐0.28, 0.83] |
| 20.4.4 Quetiapine |
1 |
95 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.14 [‐0.58, 0.29] |
| 20.4.5 Ziprasidone |
1 |
60 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.47 [‐0.98, 0.05] |
| 20.4.6 Brexpiprazole |
1 |
69 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.10 [‐1.61, ‐0.59] |
| 20.5 BPD symptom severity ‐ mood stabiliser vs placebo by substance |
3 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 20.5.1 Divalproex semisodium |
1 |
15 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.14 [‐1.22, 0.93] |
| 20.5.2 Lamotrigine |
2 |
222 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.08 [‐0.34, 0.19] |
| 20.6 Suicide‐related outcomes ‐ antipsychotics vs placebo by substance |
7 |
856 |
Std. Mean Difference (IV, Random, 95% CI) |
0.13 [‐0.08, 0.34] |
| 20.6.1 Olanzapine |
4 |
691 |
Std. Mean Difference (IV, Random, 95% CI) |
0.13 [‐0.13, 0.39] |
| 20.6.2 Ziprasidone |
1 |
60 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.27 [‐0.78, 0.23] |
| 20.6.3 Brexpiprazole |
1 |
80 |
Std. Mean Difference (IV, Random, 95% CI) |
0.28 [‐0.16, 0.72] |
| 20.6.4 Alprazolam |
1 |
25 |
Std. Mean Difference (IV, Random, 95% CI) |
0.62 [‐0.18, 1.43] |
| 20.7 Psychosocial functioning ‐ antipsychotics vs placebo by substance |
7 |
904 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.16 [‐0.33, ‐0.00] |
| 20.7.1 Haloperidol |
2 |
114 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.16 [‐1.08, 0.77] |
| 20.7.2 Olanzapine |
3 |
645 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.15 [‐0.30, 0.01] |
| 20.7.3 Quetiapine |
1 |
95 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.37 [‐0.81, 0.07] |
| 20.7.4 Thiothixene |
1 |
50 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.06 [‐0.61, 0.50] |
| 20.8 Psychosocial functioning ‐ antidepressants vs placebo by class/substance |
4 |
161 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.25 [‐0.57, 0.06] |
| 20.8.1 Tricyclic antidepressants (TCA)/amitriptyline |
2 |
119 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.20 [‐0.56, 0.16] |
| 20.8.2 Selective serotonin reuptake inhibitors (SSRIs)/fluoxetine |
2 |
42 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.40 [‐1.07, 0.27] |
